LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Urachal sinus presenting as an acute umbilical infection.

    Wu, Michael / Carroll, James / Newman, Sheri / Hayes, Ian

    ANZ journal of surgery

    2022  Volume 93, Issue 3, Page(s) 720–721

    MeSH term(s) Humans ; Infections ; Urachal Cyst ; Umbilicus ; Intraabdominal Infections
    Language English
    Publishing date 2022-07-23
    Publishing country Australia
    Document type Case Reports
    ZDB-ID 2050749-5
    ISSN 1445-2197 ; 1445-1433 ; 0004-8682
    ISSN (online) 1445-2197
    ISSN 1445-1433 ; 0004-8682
    DOI 10.1111/ans.17924
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: A case of a neuropathic diabetic foot ulcer causing rupture of the Achilles tendon.

    Saleem, Hafees Ahmad / Newman, Sheri L / Puckridge, Phillip James / Spark, James Ian

    ANZ journal of surgery

    2010  Volume 80, Issue 7-8, Page(s) 574–575

    MeSH term(s) Achilles Tendon/pathology ; Achilles Tendon/physiopathology ; Angioplasty/methods ; Diabetes Mellitus, Type 1/complications ; Diabetes Mellitus, Type 1/diagnosis ; Diabetic Foot/complications ; Diabetic Foot/diagnosis ; Diabetic Neuropathies/complications ; Diabetic Neuropathies/diagnosis ; Female ; Femoral Artery/surgery ; Follow-Up Studies ; Humans ; Middle Aged ; Peripheral Arterial Disease/diagnostic imaging ; Peripheral Arterial Disease/surgery ; Radiography ; Rupture, Spontaneous/etiology ; Rupture, Spontaneous/therapy ; Splints ; Stents ; Tendon Injuries/etiology ; Tendon Injuries/therapy ; Treatment Outcome
    Language English
    Publishing date 2010-07
    Publishing country Australia
    Document type Case Reports ; Letter
    ZDB-ID 2050749-5
    ISSN 1445-2197 ; 1445-1433 ; 0004-8682
    ISSN (online) 1445-2197
    ISSN 1445-1433 ; 0004-8682
    DOI 10.1111/j.1445-2197.2010.05369.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial.

    Basnyat, Buddha / Gertsch, Jeffrey H / Holck, Peter S / Johnson, E William / Luks, Andrew M / Donham, Benjamin P / Fleischman, Ross J / Gowder, Daniel W / Hawksworth, Jason S / Jensen, Brett T / Kleiman, Richard J / Loveridge, Adam H / Lundeen, Elizabeth B / Newman, Sheri L / Noboa, Jesse A / Miegs, Daniel P / O'Beirne, Kenneth A / Philpot, Kelly B / Schultz, Miriam N /
    Valente, Matthew C / Wiebers, Mandie R / Swenson, Erik R

    High altitude medicine & biology

    2006  Volume 7, Issue 1, Page(s) 17–27

    Abstract: 750 mg per day of acetazolamide in the prevention of acute mountain sickness (AMS), as recommended in the meta-analysis published in 2000 in the British Medical Journal, may be excessive and is controversial. To determine if the efficacy of low-dose ... ...

    Abstract 750 mg per day of acetazolamide in the prevention of acute mountain sickness (AMS), as recommended in the meta-analysis published in 2000 in the British Medical Journal, may be excessive and is controversial. To determine if the efficacy of low-dose acetazolamide 125 mg bd (250 mg), as currently used in the Himalayas, is significantly different from 375 mg bd (750 mg) of acetazolamide in the prevention of AMS, we designed a prospective, double-blind, randomized, placebo-controlled trial. The participants were sampled from a diverse population of (non-Nepali) trekkers at Namche Bazaar (3440 m) in Nepal on the Everest trekking route as they ascended to study midpoints (4280 m/4358 m) and the endpoint, Lobuje (4928 m), where data were collected. Participants were randomly assigned to receive 375 mg bd of acetazolamide (82 participants), 125 mg bd of acetazolamide (74 participants), or a placebo (66 participants), beginning at 3440 m for up to 6 days as they ascended to 4928 m. The results revealed that composite AMS incidence for 125 mg bd was similar to the incidence for 375 mg bd (24% vs. 21%, 95% confidence interval, -12.6%, 19.8%), in contrast to significantly greater AMS (51%) observed in the placebo group (95% confidence interval for differences: 8%, 46%; 12%, 49% for low and high comparisons, respectively). Both doses of acetazolamide improved oxygenation equally (82.9% for 250 mg daily and 82.8% for 750 mg daily), while placebo endpoint oxygen saturation was significantly less at 80.7% (95% confidence interval for differences: 0.5%, 3.9% and 0.4%, 3.7% for low and high comparisons, respectively). There was also more paresthesia in the 375-mg bd group (p < 0.02). We conclude that 125 mg bd of acetazolamide is not significantly different from 375 mg bd in the prevention of AMS; 125 mg bd should be considered the preferred dosage when indicated for persons ascending to altitudes above 2500 m.
    MeSH term(s) Acetazolamide/administration & dosage ; Adult ; Altitude ; Altitude Sickness/drug therapy ; Altitude Sickness/prevention & control ; Carbonic Anhydrase Inhibitors/administration & dosage ; Confidence Intervals ; Dose-Response Relationship, Drug ; Double-Blind Method ; Female ; Humans ; Male ; Mountaineering ; Nepal ; Odds Ratio ; Prospective Studies ; Pulmonary Edema/prevention & control ; Treatment Outcome
    Chemical Substances Carbonic Anhydrase Inhibitors ; Acetazolamide (O3FX965V0I)
    Language English
    Publishing date 2006
    Publishing country United States
    Document type Journal Article ; Randomized Controlled Trial
    ZDB-ID 2076262-8
    ISSN 1527-0297
    ISSN 1527-0297
    DOI 10.1089/ham.2006.7.17
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top